These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 16722814)

  • 21. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
    Foote M
    Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
    Vishnu P; Roy V
    Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients.
    Borgå O; Lilienberg E; Bjermo H; Hansson F; Heldring N; Dediu R
    Adv Ther; 2019 Oct; 36(10):2825-2837. PubMed ID: 31432461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
    Stinchcombe TE
    Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
    Li Y; Chen N; Palmisano M; Zhou S
    Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
    Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
    BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.
    Moreno-Aspitia A; Perez EA
    Future Oncol; 2005 Dec; 1(6):755-62. PubMed ID: 16556053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
    Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
    Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
    Montero AJ; Adams B; Diaz-Montero CM; Glück S
    Expert Rev Clin Pharmacol; 2011 May; 4(3):329-34. PubMed ID: 22114779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nab-paclitaxel].
    Lopez-Trabada Ataz D; Dumont S; André T
    Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
    J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
    Kundranda MN; Niu J
    Drug Des Devel Ther; 2015; 9():3767-77. PubMed ID: 26244011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
    Schettini F; Giuliano M; De Placido S; Arpino G
    Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The winning formulation: the development of paclitaxel in pancreatic cancer.
    Ma WW; Hidalgo M
    Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
    Liang C; Li L; Fraser CD; Ko A; Corzo D; Enger C; Patt D
    BMC Cancer; 2015 Dec; 15():1019. PubMed ID: 26714468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.
    Hoy SM
    Drugs; 2014 Oct; 74(15):1757-68. PubMed ID: 25260887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.
    Fu Q; Sun J; Zhang W; Sui X; Yan Z; He Z
    Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):262-72. PubMed ID: 19538176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.
    Biakhov MY; Kononova GV; Iglesias J; Desai N; Bhar P; Schmid AN; Loibl S
    Expert Opin Drug Saf; 2010 Jul; 9(4):515-23. PubMed ID: 20500029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
    Ciruelos E; Jackisch C
    Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.